Jan 2018
The NSW Government has launched the country’s first cannabis medicines hotline. The hotline – part of a $21 million investment in cannabis medicines research – will simplify and speed up access for doctors whose patients may benefit from this type of treatment. The service will provide guidance for the use of cannabis medicines, including advice on clinical management, available medicines, and dosage information.
LEARN MORE >
Perth’s first medicinal cannabis clinic has been opened in Subiaco. This clinic is the fourth location in Australia and has been set up to streamline access to medicinal cannabis and help to speed up the application process.
A new law has been passed by the New Zealand Government which will allow terminally ill patients to access cannabis for medicinal use. The law will also allow medicinal cannabis to be manufactured in the country and exported overseas. New regulations are expected to be in place within a year.
A new world-first trial will examine whether oral medicinal cannabis can affect tumour growth in patients with glioma, a common type of brain cancer.
A new survey has found that even though the cost of medicinal cannabis has significantly decreased over the past year the pricing is still too high for many Australians.
Olivia Newton-John, who is battling cancer for the third time, has revealed that following radiation therapy she been using cannabis oil to treat her cancer symptoms, such as pain.
Despite medicinal cannabis being decriminalized across the country, due to uneven legislation across states governing the prescription and use of medical cannabis, it remains difficult to source.
Sydney businessman Barry Lambert, who was found guilty of possession and cultivation of cannabis in 2017, claims that hemp extract was the only thing that helped to stop his granddaughter’s seizures.
Latest data shows that since it became easier for doctors to prescribe medicinal cannabis in New South Wales, 322 applications have been approved.
A study conducted by researchers from The Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney found that almost two thirds of 640 Australian GPs surveyed have had patients ask about the drug.
A study conducted by researchers from The Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney found that almost two thirds of 640 Australian GPs surveyed have had patients ask about the drug.
TEN NEW MEDICINAL CANNABIS CLINICS TO OPEN IN MELBOURNE THIS […]
AUSTRALIAN PATIENTS TRAVELLING OVERSEAS FOR MEDICINAL CANNABIS Eighteen months on from […]
MEDICINAL CANNABIS EXPORTS APPROVED BY FEDERAL GOVERNMENT Following an extensive […]
MEDICINAL CANNABIS IN AUSTRALIA: HOW LEGAL IS IT? Following the […]
FIRST AUSTRALIAN TRIAL TO EXPLORE EFFECTS OF MEDICINAL CANNABIS ON […]
VICTORIAN CHILDREN TO ACCESS MEDICAL CANNABIS IN EPILEPSY TRIAL Twenty-nine […]
UNIFIED ACCESS SYSTEM FOR MEDICAL CANNABIS NEEDED Blue Mountains GP […]
The Commonwealth Department of Health, in conjunction with state and territory governments, has helped coordinate the development new clinical guidance documents for medicinal cannabis products.
MEDICINAL CANNABIS ACCESS REGULATIONS ‘UNWORKABLE’ An Adelaide GP has criticised […]
ADMINISTRATIVE OBSTACLES SLOW MEDICINAL CANNABIS UPTAKE IN NSW In the […]
LUCY HASLAM STRIVES TO IMPROVE MEDICINAL CANNABIS ACCESS FOR PATIENTS […]
RACGP PRESIDENT CRITICISES MEDICAL CANNABIS REGULATION The Royal College of […]
FIRST TASMANIANS APPROVED UNDER NEW SCHEME TO USE MEDICINAL CANNABIS […]
Liberal Democrats Senator David Leyonhjelm has called on the federal government to ‘quit dithering’ and cut the red tape preventing thousands of Australians suffering chronic pain from accessing medicinal cannabis.
NSW GOVERNMENT ACCUSED OF DELAYING ACCESS TO MEDICAL CANNABIS Shadow […]
QUEENSLAND LEADS WITH WORLD-FIRST MEDICINAL CANNABIS TRIAL A Queensland trial […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla at massa in neque egestas pellentesque. Donec nec urna sodales, bibendum justo vel, porta libero. Praesent id libero eros. Nullam elementum, ipsum ac hendrerit suscipit, risus mi feugiat erat, quis faucibus eros velit et turpis.
The aim of the survey completed by 640 Australian general practitioners (GP) was to examine the knowledge and attitudes of GP towards medicinal cannabis. The results show that the majority of surveyed practitioners are supportive or neutral when it comes to medicinal cannabis use.
The results show that medicinal cannabis can significantly affect levels of the appetite hormones and be considered as a supporting medicine when treating eating disorders and obesity.
The results show that medicinal cannabis has a reasonable safety profile and can help with pain management, quality of life and cognitive function.
This review of 49 studies assesses the use of medicinal cannabis for anxiety-related disorders. The available evidences demonstrates there is a potential benefit of cannabinoids in reducing anxiety behaviors relevant to disorders such as PTSD, GAD, PD, OCD, and SAD, with no anxiogenic effects. The authors emphasise the potential value and need for further study of CBD in the treatment of anxiety disorders.
The review of 24 reports evaluates the use of medicinal cannabis for psychiatric, movement and neurodegenerative disorders. The available evidences suggest there is a potential benefit of cannabinoids for those diseases however further research is required to confirm its efficacy.
A double-blind, placebo-controlled trial on 120 children and young adults with the Dravet syndrome and drug-resistant seizures shows that cannabidiol reduces the frequency of convulsive seizures.
Systematic review of 13 studies shows that cannabis-based medicinal extracts may provide effective pain relief to patients suffering with chronic nonmalignant neuropathic pain, especially with conditions that are resistant to other treatments.
The study collected data from 65 families to explore their experiences with medicinal cannabis to help treat their children’s epilepsy.
The review of preclinical studies outlining the role of cannabinoids in the modulation of headache pathogenesis.
Study assessing the efficacy and safety of cannabidiol as an add-on anticonvulsant
A systematic review and meta-analysis on the efficacy, tolerability, and safety of cannabinoids in palliative medicine.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.
LEARN ABOUT ANTG HERE >
